Safety and Chemopreventive Effect of Polyphenon E in Preventing Early and Metastatic Progression of Prostate Cancer in TRAMP Mice

被引:18
|
作者
Kim, Seung Joon [1 ]
Amankwah, Ernest [2 ]
Connors, Shahnjayla [8 ]
Park, Hyun Y. [2 ]
Rincon, Maria [2 ]
Cornnell, Heather [7 ]
Chornokur, Ganna [2 ]
Hashim, Arig Ibrahim [3 ]
Choi, Junsung [4 ]
Tsai, Ya-Yu [2 ]
Engelman, Robert W. [5 ,6 ]
Kumar, Nagi [2 ]
Park, Jong Y. [2 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Canc Epidemiol, Tampa, FL 33682 USA
[3] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Imaging Res, Tampa, FL 33682 USA
[4] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Diagnost Imaging & Intervent Radiol, Tampa, FL 33682 USA
[5] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pathol & Cell Biol, Tampa, FL 33682 USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pediat, Tampa, FL 33682 USA
[7] Florida Hosp, Sanford Burnham Med Res Inst, Orlando, FL USA
[8] Washington Univ, Dept Surg, Div Publ Hlth Sci, St Louis, MO USA
关键词
GREEN TEA POLYPHENOLS; CELLS IN-VITRO; EPIGALLOCATECHIN GALLATE; INTRAEPITHELIAL NEOPLASIA; PROTEASOME ACTIVITY; SYNTHETIC ANALOGS; DRUG DEVELOPMENT; CARCINOMA-CELLS; DIETARY AGENTS; BREAST-CANCER;
D O I
10.1158/1940-6207.CAPR-13-0427-T
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer treatment is often accompanied by untoward side effects. Therefore, chemoprevention to reduce the risk and inhibit the progression of prostate cancer may be an effective approach to reducing disease burden. We investigated the safety and efficacy of Polyphenon E, a green tea extract, in reducing the progression of prostate cancer in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. A total of 119 male TRAMP and 119 C57BL/6J mice were treated orally with one of 3 doses of Polyphenon E (200, 500, and 1,000 mg/kg/day) in drinking water ad libitum replicating human achievable doses. Baseline assessments were performed before treatments. Safety and efficacy assessments during treatments were performed when mice were 12, 22, and 32 weeks old. The number and size of tumors in treated TRAMP mice were significantly decreased compared with untreated animals. In untreated 32 weeks old TRAMP mice, prostate carcinoma metastasis to distant sites was observed in 100% of mice (8/8), compared with 13% of mice (2/16) treated with high-dose Polyphenon E during the same period. Furthermore, Polyphenon E treatment significantly inhibited metastasis in TRAMP mice in a dose-dependent manner (P=0.0003). Long-term (32 weeks) treatment with Polyphenon E was safe and well tolerated with no evidence of toxicity in C57BL/6J mice. Polyphenon E is an effective chemopreventive agent in preventing the progression of prostate cancer to metastasis in TRAMP mice. Polyphenon E showed no toxicity in these mouse models. Our findings provide additional evidence for the safety and chemopreventive effect of Polyphenon E in preventing metastatic progression of prostate cancer.(c) 2014 AACR.
引用
收藏
页码:435 / 444
页数:10
相关论文
共 50 条
  • [41] Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer - Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice
    Williams, TM
    Hassan, GS
    Li, JW
    Cohen, AW
    Medina, F
    Frank, PG
    Pestell, RG
    Di Vizio, D
    Loda, M
    Lisanti, MP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (26) : 25134 - 25145
  • [42] Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1;: Pten mice
    Gao, Hui
    Ouyang, Xuesong
    Banach-Petrosky, Whitney A.
    Shen, Michael M.
    Abate-Shen, Cory
    CANCER RESEARCH, 2006, 66 (16) : 7929 - 7933
  • [43] A critical role of E-cadherin expression during the progression of metastatic prostate cancer cells with the microenvironment as a driving force
    Yates, Clayton C., III
    Shepherd, Chris
    Wells, Alan
    CANCER RESEARCH, 2006, 66 (08)
  • [44] Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish Early Access Programme
    Aparicio, L. A.
    Sanchez-Hernandez, A.
    Esteban, E.
    Germa, J. R.
    Batista, N.
    Maroto, P.
    Perez-Valderrama, B.
    Luque, R.
    Garcia Palomo, A.
    Castellano, D. E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S694 - S694
  • [45] Early PSA progression in abiraterone/enzalutamide-treated patients with metastatic castration-resistant prostate cancer.
    Lopez-Campos, Fernando
    Gomez-Iturriaga, Alfonso
    Llacer Perez, Casilda
    Henriquez, Ivan
    Peleteiro, Paula
    Lozano, Rebeca
    Castano, Ana
    Romero-Laorden, Nuria
    Molina-Cerrillo, Javier
    Alvarez-Rodriguez, Sara
    Piquer, Teresa
    Navarro-Castellon, Joaquin
    Jose Conde-Moreno, Antonio
    Ramirez-Backhaus, Miguel
    Barrionuevo, Patricia
    Garcia, Raquel
    de los Llanos Perez-Haro, Maria
    Castro, Elena
    Olmos, David
    Lorente, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Systemic Ablation of Camkk2 Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer
    Pulliam, Thomas L.
    Awad, Dominik
    Han, Jenny J.
    Murray, Mollianne M.
    Ackroyd, Jeffrey J.
    Goli, Pavithr
    Oakhill, Jonathan S.
    Scott, John W.
    Ittmann, Michael M.
    Frigo, Daniel E.
    CELLS, 2022, 11 (12)
  • [47] Early Real-world Safety Data of Darolutamide in Non-metastatic Castrate-resistant Prostate Cancer
    Elumalai, T.
    Syndikus, I.
    Sundar, S.
    Choudhury, A.
    Conroy, R.
    Birtle, A.
    CLINICAL ONCOLOGY, 2022, 34 (03) : E144 - E145
  • [48] Effect of baseline metabolic aberrations in men with locally advanced/metastatic prostate cancer treated with ADT on time to disease progression, prostate cancer specific and all cause death
    Crawley, D.
    van Hemelrijck, M.
    Chowdhury, S.
    James, N.
    Gilson, C.
    Spears, M.
    Sydes, M. R.
    Rudman, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer
    Bracarda, Sergio
    Gernone, Angela
    Gasparro, Donatello
    Marchetti, Paolo
    Ronzoni, Monica
    Bortolus, Roberto
    Fratino, Lucia
    Basso, Umberto
    Mazzanti, Roberto
    Messina, Caterina
    Tucci, Marcello
    Boccardo, Francesco
    Carteni, Giacomo
    Pinto, Carmine
    Fornarini, Giuseppe
    Mattioli, Rodolfo
    Procopio, Giuseppe
    Chiuri, Vincenzo
    Scotto, Tiziana
    Dondi, Davide
    Di Lorenzo, Giuseppe
    FUTURE ONCOLOGY, 2014, 10 (06) : 975 - 983
  • [50] Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program
    Parente, Phillip
    Ng, Siobhan
    Parnis, Francis
    Guminski, Alex
    Gurney, Howard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (06) : 391 - 399